NCT06995898 The Vanguard Study: Testing a New Way to Screen for Cancer
| NCT ID | NCT06995898 |
| Status | Recruiting |
| Phase | — |
| Sponsor | National Cancer Institute (NCI) |
| Condition | Bladder Carcinoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 24,000 participants |
| Start Date | 2025-06-18 |
| Primary Completion | 2029-01-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 24,000 participants in total. It began in 2025-06-18 with a primary completion date of 2029-01-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The Vanguard Study is a feasibility study to explore several aspects of evaluating multi-cancer detection (MCD) tests in a future definitive randomized controlled trial. An MCD test measures markers in the blood in order to screen for multiple cancers simultaneously. There is a need to understand how MCDs may work as cancer screening tools. The goal of cancer screening is to reduce the burden of cancer by identifying cancers before they show symptoms or signs, when treatment is likely to be most effective. In this study, adults aged 45-75 without cancer will be randomly assigned to one of 3 groups: 2 separate MCD test groups or a control group. These two MCD tests will not be compared to each other but will be compared to cancers detected in the control group. This study will provide early information on how well MCD tests perform as cancer screening tools. It will also help researchers understand how patients and their doctors make decisions about their care when the MCD test result comes back as normal (negative) or abnormal (positive).
Eligibility Criteria
Inclusion Criteria: * Ages 45-75 years old * Agree to provide blood samples for possible MCD testing at enrollment and at 1 year following enrollment * Agree to allow collection of information from their medical records for study-related purposes * Understand and be able to complete informed consent and participant questionnaires in English, Spanish, or Arabic * Note: Eligibility for Spanish and Arabic languages are at the Hub's discretion Exclusion Criteria: * Solid malignant tumor or blood cancer diagnosis, with or without treatment, within the last 5 years * Note: Persons with a history of in situ cancers (e.g., ductal carcinoma in situ of the breast, cervical cancer in situ, atypical melanocytic hyperplasia or melanoma in situ) or nonmelanoma skin cancer are eligible * Ongoing cancer diagnostic work-up * Ongoing participation in another study of an investigational cancer screening test or technology * Currently breastfeeding or pregnant, or planning to become pregnant in the next year
Contact & Investigator
Scott D Ramsey
PRINCIPAL INVESTIGATOR
Fred Hutchinson Cancer Center
Frequently Asked Questions
Who can join the NCT06995898 clinical trial?
This trial is open to participants of all sexes, aged 45 Years or older, up to 75 Years, studying Bladder Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06995898 currently recruiting?
Yes, NCT06995898 is actively recruiting participants. Visit ClinicalTrials.gov or contact National Cancer Institute (NCI) to inquire about joining.
Where is the NCT06995898 trial being conducted?
This trial is being conducted at Pleasanton, United States, Cheyenne Wells, United States, Denver, United States, Fort Collins, United States and 11 additional locations.
Who is sponsoring the NCT06995898 clinical trial?
NCT06995898 is sponsored by National Cancer Institute (NCI). The principal investigator is Scott D Ramsey at Fred Hutchinson Cancer Center. The trial plans to enroll 24,000 participants.